NDC 10019-944-50 - CYCLOPHOSPHAMIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 10019-944
- Requested NDC
- 10019-944-50
- Package NDCs from labels
- 10019-944-50, 10019-944-01
- Manufacturer
- Baxter Healthcare Company
- Effective date
- 2017-03-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| CYCLOPHOSPHAMIDE - Baxter Healthcare Company | Baxter Healthcare Company | 2017-03-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10019-944-01 | CYCLOPHOSPHAMIDE | 1 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 1 | 15 | |
| 10019-944-50 | CYCLOPHOSPHAMIDE | 50 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 50 | 15 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 10019-944-01 | EA - Each | 10019-944 | f3d382ad-80b6-45b2-a131-c224e6cbb4d9 | 1 | 2015-01-05 |
| 10019-944-50 | EA - Each | 10019-944 | d2d586f9-63c6-4409-bcf2-8eb4bbc25d79 | 1 | 2015-04-03 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | ACTIVE INGREDIENT | 8N3DW7272P | CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION] | 2 | |
| CYCLOPHOSPHAMIDE ANHYDROUS | ACTIVE MOIETY | 6UXW23996M | CYCLOPHOSPHAMIDE INJECTION, POWDER, FOR SOLUTION [BAXTER HEALTHCARE CORPORATION] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Alembic Pharmaceuticals Inc. | 3d6e68b1-5120-4cbb-a9d2-fb09d1b74ea1 | 2024-12-10 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | NorthStar Rx LLC | 76f057be-e3da-0a89-e053-2a91aa0a8438 | 2024-11-20 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Hikma Pharmaceuticals USA Inc. | 8135b917-882f-4b4c-99b7-fa8ea54af4bf | 2024-11-19 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Fresenius Kabi USA, LLC | 31986d36-a1bf-4903-93a4-ce7386241ba1 | 2024-10-09 | Warnings, Adverse reactions | 1734921 1734917 1734919 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Avyxa Pharma, LLC | 6f593585-e0dd-48bc-bd2b-c6c787e0b98c | 2024-07-26 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | Baxter Healthcare Company | 34dbffee-80e0-49c3-90e8-95713a0b7fbe | 2024-04-10 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Baxter Healthcare Corporation | 769ded74-6186-40a8-8e44-ceff67287451 | 2020-08-07 | Warnings, Adverse reactions | 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | cef038cc-efab-46d9-99c2-95bb11d6c9bc | 2017-03-15 | Warnings, Adverse reactions | ANDA040745 10019-944-50 10019-944-01 10019-943-25 10019-943-01 10019-945-01 10019-945-10 10019-944 10019-945 10019-943 10019094450 1734921 1734917 1734919 3d950615-927d-441e-b3be-0cebda594df5 cef038cc-efab-46d9-99c2-95bb11d6c9bc 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 6bae5c14-9e87-4fb6-ae9c-4d875c1ecffe | 2017-03-15 | Warnings, Adverse reactions | ANDA040745 1734921 1734917 1734919 8N3DW7272P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.